Public Equities, L.P.Invus ... Net Worth

The estimated Net Worth of Public Equities, L.P.Invus ... is at least $9.4 Million dollars as of 8 December 2020. Public Invus owns over 790,000 units of Seer stock worth over $9,403,867 and over the last 4 years Public sold SEER stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Public Invus SEER stock SEC Form 4 insiders trading

Public has made over 1 trades of the Seer stock since 2020, according to the Form 4 filled with the SEC. Most recently Public bought 790,000 units of SEER stock worth $15,010,000 on 8 December 2020.

The largest trade Public's ever made was buying 790,000 units of Seer stock on 8 December 2020 worth over $15,010,000. On average, Public trades about 790,000 units every 0 days since 2020. As of 8 December 2020 Public still owns at least 5,840,911 units of Seer stock.

You can see the complete history of Public Invus stock trades at the bottom of the page.

Insiders trading at Seer

Over the last 7 years, insiders at Seer have traded over $150,878,393 worth of Seer stock and bought 1,798,420 units worth $33,507,980 . The most active insiders traders include Omid Farokhzad, Terrance Mcguire und Growth Fund Limited Partner.... On average, Seer executives and independent directors trade stock every 60 days with the average trade being worth of $227,813. The most recent stock trade was executed by Dipchand Nishar on 14 June 2024, trading 12,109 units of SEER stock currently worth $21,554.

What does Seer do?

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Complete history of Public Invus stock trades at Seer

Seer executives and stock owners

Seer executives and other stock owners filed with the SEC include:

• Dr. Omid C. Farokhzad M.D., Ph.D.,
  Founder, CEO & Chair of the Board of Directors
• Dr. Omid C. Farokhzad Ph.D., M.D.,
  CEO & Chair of the Board of Directors
• Omead Ostadan,
  Part Time Pres, COO & Director
• David R. Horn,
  Exec. VP & Chief Financial Officer
• Martin Goldberg Ph.D.,
  Sr. VP of Devel.
• Elona Kogan Esq., J.D.,
  Gen. Counsel & Sec.
• Marissa Dixon,
  VP & Chief People Officer
• Jennifer Maggio,
  VP & Corp. Controller
• Dr. Serafim Batzoglou,
  VP & Chief of Computation
• Shashanka Muppaneni,
  VP of Corp. Devel.
• Karen Possemato,
  VP of Corp. Marketing & Communications
• Elona Kogan J.D., Esq.,
  Gen. Counsel & Sec.
• Dr. Philip Ma Ph.D.,
  Founder & Strategic Advisor
• Joe Laws,
  Chief Technology Officer and Co-Founder
• David Hallal,
  
• Rachel E. Haurwitz,
  
• Dipchand Nishar,
  
• Mostafa Ronaghi,
  Director
• David B Singer,
  Director
• Public Equities, L.P.Invus ...,
  
• Omead Ostadan,
  President & COO
• David R. Horn,
  PRESIDENT & CFO
• Growth Fund Limited Partner...,
  
• Capital Ventures, Llc Maver...,
  
• Cathy Friedman,
  Director
• Terrance Mcguire,
  
• Capital Ventures, Llc Maver...,
  
• Robert Langer,
  
• Scott D Thomas,
  Chief Commercial Officer
• Public Equities, L.P.Artal ...,
  
• Meeta Gulyani,
  
• Omid Farokhzad,
  CEO AND CHAIR
• Elona Kogan,
  CHIEF LEGAL OFFICER
• Nicolas H Phd Roelofs,